UBS analyst Colin Bristow raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $167.00 (from $164.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE